NCT06692348View on ClinicalTrials.gov

A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

June 9, 2025

Study Completion Date

June 9, 2025

Conditions
Healthy
Interventions
DRUG

Orforglipron

Administered orally

Trial Locations (3)

532-0003

Medical Corporation Heishinkai OPHAC Hospital, Osaka

130-0004

Sumida Hospital, Sumida-ku

812-0025

Hakata Clinic, Fukuoka

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06692348 - A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants | Biotech Hunter | Biotech Hunter